Abstract
Some of the differences in the proliferative kinetics of normal and malignant tissues may be used to increase radiation damage to tumor cells. Of these various possibilities, some are still at a theoretical stage (mainly because there are no means of obtaining the needed data) but others, notably those involving a combination of cycle-linked chemotherapeutic and/or radiosensitizing drugs with radiation, may be exploitable now with the expectation of clinical benefit.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
